비교리스트

 카트 문의
시장보고서
상품코드
1610892

세계의 감염병 진단 시장 : 인사이트, 경쟁, 시장 예측(-2030년)

Infectious Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

감염병 진단 시장 규모는 2023년 385억 2,000만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 3.80%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 481억 달러에 달할 것으로 예상됩니다. 감염성 질환 진단 시장은 HIV, B형 및 C형 간염, 독감 등 감염성 질환 환자 증가와 주요 기업들의 혁신적인 신제품 출시로 인해 크게 성장하고 있으며, 이는 2024년부터 2030년까지 예측 기간 동안 전체 감염성 질환 진단 시장의 성장에 기여하는 주요 요인으로 작용할 것으로 보입니다.

세계보건기구(WHO)의 2024년 발표에 따르면, 2022년에는 전 세계적으로 약 3,900만 명이 HIV 감염증을 앓고 있다고 합니다. 이 중 약 3,750만 명은 성인(15세 이상)이고, 약 150만 명은 15세 미만의 어린이라고 합니다. 감염 진단은 HIV 감염을 확인하고 조기 발견, 치료 모니터링, 감염 예방을 가능하게 하는 데 있어 매우 중요합니다. 분자 검사, 항원 및 항체 검사, 현장 검사 등의 기술은 HIV 진단, 바이러스 양 평가, 치료 방침 결정에 널리 사용되고 있습니다.

또한, 시장 업체들의 혁신적인 신제품 출시로 인해 시장 점유율이 상승하고 있습니다. 예를 들어, 2023년 2월 Thermo Fisher는 인도에서 감염성 질환 검출을 위한 실시간 PCR 키트를 출시했으며, Applied Biosystems의 TaqPath PCR 키트는 다제내성 결핵(MDR-TB), MTB, B형 간염(HBV), C형 간염(HCV)을 진단할 수 있도록 설계되었습니다, HIV, HLA-B27 등의 유전자 분석 등 진단 개발 및 검사에 신뢰성을 제공하도록 설계되었습니다.

따라서 2024년부터 2030년까지의 예측 기간 동안 위의 모든 요인들이 복합적으로 작용하여 감염성 질환 진단 시장을 견인할 것으로 예상됩니다.

이 보고서는 세계 감염병 진단 시장을 조사했으며, 시장 개요와 함께 유형별, 기술별, 기법별, 용도별, 최종사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 감염병 진단 시장 보고서 서론

제2장 감염병 진단 시장 주요 요약

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 감염병 진단 시장의 주요 요인 분석

  • 감염병 진단 시장 성장 촉진요인
  • 감염병 진단 시장 성장 억제요인과 과제
  • 감염병 진단 시장 기회

제6장 감염병 진단 시장 : Porter의 Five Forces 분석

제7장 감염병 진단 시장 평가

  • 유형별
  • 기술별
  • 기법별
  • 용도별
  • 최종사용자별
  • 지역별

제8장 감염병 진단 시장 기업과 제품 개요

  • BD
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • bioMerieux SA
  • QIAGEN
  • DiaSorin S.p.A
  • Meridian Bioscience, Inc.
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
  • Cepheid
  • Siemens Healthcare GmbH
  • Ortho Clinical Diagnostics
  • Biocare Medical, LLC.
  • Bruker
  • Cardinal Health
  • Chembio Diagnostics, Inc.
  • Novacyt
  • Trinity Biotech
  • OJ-Bio Limited

제9장 KOL(Key Opinion Leader)의 견해

제10장 프로젝트 접근

제11장 DelveInsight에 대해

제12장 면책사항과 문의

LSH 24.12.24

Infectious disease diagnostic market by Type (Products [Instruments and Reagents & Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others), Technique (Polymerase chain reaction (PCR), Nucleic Acid Amplification Tests (NAAT), ELISA, Rapid immunochromatography assays, and Others), Application (Viral Diseases, Bacterial Diseases, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of infectious diseases and the rising product developmental activities worldwide

The infectious disease diagnostics market was valued at USD 38.52 billion in 2023 and is estimated to grow at a CAGR of 3.80% during the forecast period from 2024 to 2030 to reach USD 48.10 billion by 2030. The infectious disease diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B & C, and influenza, the introduction of new and innovative products by key players, and others that are acting as major factors contributing to the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

Infectious Disease Diagnostics Market Dynamics:

As per the World Health Organization (WHO) 2024, nearly 39 million people were living with HIV infection in 2022, globally. The source also stated that nearly 37.5 million were adults (aged 15 and above) and approximately 1.5 million people were children, aged less than 15 years. Infectious disease diagnostics are crucial in identifying HIV infection, enabling early detection, treatment monitoring, and preventing transmission. Techniques such as molecular testing, antigen/antibody assays, and point-of-care tests are widely used to diagnose HIV, assess viral load, and guide therapy decisions.

Data from the WHO 2024, stated that 304 million people were infected by hepatitis B and C across the world in the year 2022. The same source further stated that out of these 254 million were afflicted by hepatitis B and 50 million were affected by hepatitis C. Infectious disease diagnostics enable early detection and treatment of hepatitis B and C through techniques like serology, nucleic acid testing, and rapid diagnostics, helping to control and prevent transmission.

Additionally, the introduction of new and innovative products by market players are pushing forward the market share for same. For example, in February 2023, Thermo Fisher introduced real-time PCR kits in India for the detection of infectious diseases. The Applied Biosystems TaqPath PCR kits are designed to provide confidence and reliability in diagnostic development and testing for conditions like Multi-Drug Resistant Tuberculosis (MDR-TB), M. Tuberculosis complex (MTB), Hepatitis B (HBV), Hepatitis C (HCV), HIV, and for genetic analysis such as HLA-B27.

Hence, the interplay of all the above-mentioned factors is expected to drive the market for infectious disease diagnostics during the given forecast period from 2024 to 2030.

However, the risk of sample contamination during transport and storage, among other factors may prove to be challenging factors for the growth of the infectious disease diagnostics market.

Infectious Disease Diagnostics Market Segment Analysis:

Infectious disease diagnostic market by Type (Products [Instruments and Reagents & Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others), Technique (Polymerase chain reaction (PCR), Nucleic Acid Amplification Tests (NAAT), ELISA, Rapid immunochromatography assays, and Others), Application (Viral Diseases, Bacterial Diseases, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment of the infectious disease diagnostics market, the immunoassays category is expected to have a significant revenue share in 2023. This is due to the various features and applications of immunoassays in diagnostics.

Immunoassay technology utilizes antibodies to identify and quantify pathogens, including viruses, bacteria, and other infectious agents. The key advantage of immunoassays is their sensitivity and specificity, which allow for the accurate detection of low levels of antigens or antibodies in patient samples. This is particularly valuable for early diagnosis and screening of diseases such as HIV, hepatitis, and influenza. Furthermore, immunoassays can be designed for high throughput, enabling the simultaneous testing of multiple samples, which is essential in outbreak situations. The technology also supports point-of-care testing, providing rapid results that facilitate timely clinical decision-making.

Additionally, in July 2023, Roche Diagnostics India announced the launch of the Elecsys(R) HCV Duo, India's first commercially available fully automated immunoassay. This assay enables the simultaneous and independent determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.

Therefore, the widespread uses of immunoassay in diagnostics, solidify the impact on the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall infectious disease diagnostics market:

Among all the regions, North America is estimated to hold a significant revenue share in the infectious disease diagnostics market. This domination is due to the growing burden of infectious diseases including tuberculosis, outbreaks of influenza, emerging pathogens, growing product developmental activities, presence of key manufacturers, among others that are expected to fuel the infectious disease diagnostics market in the region during forecast period from 2024 to 2030.

Public Health Agency of Canada (2024), stated that in 2022, there were 1,971 active tuberculosis cases in Canada. Infectious disease diagnostics is essential for the detection and identification of tuberculosis, utilizing techniques such as molecular testing, culture, and imaging. These methods facilitate prompt treatment, track disease transmission, and guide public health measures to manage outbreaks effectively.

Advancements in technology, such as the development of rapid diagnostic tests and molecular assays, enhance the accuracy and speed of diagnoses, making testing more accessible. The increase in point-of-care testing is also contributing to the market, allowing immediate results in clinical settings.

Rising product developmental activities by regulatory bodies in the region are likely to push forward the revenue shares for the same. For example, in November 2023, Abbott announced that it received the U.S. Food and Drug Administration (FDA) approval for its human papillomavirus or HPV screening solution.

Therefore, the interplay of all the factors mentioned above provide a conducive growth environment for the North America region in the infectious disease diagnostics market during the forecast period from 2024 to 2030.

Infectious Disease Diagnostics Market key players:

Some of the key market players operating in the infectious disease diagnostics market include BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Abbott, bioMerieux SA, QIAGEN, DiaSorin S.p.A, Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC., Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

Recent Developmental Activities in the Infectious Disease Diagnostics Market:

  • In May 2024, Karius announced that its Karius Test, designed for diagnosing and managing lung infections in immunocompromised patients, received breakthrough device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
  • In May 2022, BD announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.
  • In December 2021, Roche announced the launch of the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.

Key takeaways from the Infectious Disease Diagnostics Market Report study

  • Market size analysis for current infectious disease diagnostics market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the infectious disease diagnostics market
  • Various opportunities available for other competitors in the infectious disease diagnostics market space
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current infectious disease diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for infectious disease diagnostics market growth in the coming future?

Target audience who can be benefited from this infectious disease diagnostics market report study

  • Infectious disease diagnostics providers
  • Research organizations and consulting companies
  • Infectious disease diagnostics related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in infectious disease diagnostics
  • Various end-users who want to know more about the infectious disease diagnostics market and the latest developments in the infectious disease diagnostics market

Frequently Asked Questions for the Infectious Disease Diagnostics Market:

1. What are Infectious Disease Diagnostics?

The infectious disease diagnostics comprises of diagnostic tests, assays, instruments, and others that are utilized for the detection and identification of causative agents responsible for the disease.

2. What is the market for Infectious Disease Diagnostics?

The infectious disease diagnostics market was valued at USD 38.52 billion in 2023 and is estimated to grow at a CAGR of 3.80% during the forecast period from 2024 to 2030 to reach USD 48.10 billion by 2030.

3. What are the drivers for the Infectious Disease Diagnostics market?

The infectious disease diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B & C, influenza, introduction of new and innovative products by key players, and others that are acting as major factors contributing to the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Infectious Disease Diagnostics market?

Some of the major market players operating in the infectious disease diagnostics market include BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Abbott, bioMerieux SA, QIAGEN, DiaSorin S.p.A, Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC., Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

5. Which region has the highest share in the Infectious Disease Diagnostics market?

Among all the regions, North America is estimated to hold a significant revenue share in the infectious disease diagnostics market. This domination is due to the growing burden of infectious diseases including tuberculosis, outbreaks of influenza, emerging pathogens, growing product developmental activities, presence of key manufacturers, among others that are expected to fuel the infectious disease diagnostics market in the region during the forecast period from 2024 to 2030.

Table of Contents

1. Infectious Disease Diagnostics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Infectious Disease Diagnostics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Infectious Disease Diagnostics Market Key Factors Analysis

  • 5.1. Infectious Disease Diagnostics Market Drivers
    • 5.1.1. Increasing cases of infectious diseases
    • 5.1.2. Rising product developmental activities
    • 5.1.3. Technological advancements in diagnostics
  • 5.2. Infectious Disease Diagnostics Market Restraints and Challenges
    • 5.2.1. Risk of sample contamination during transport and storage
  • 5.3. Infectious Disease Diagnostics Market Opportunities
    • 5.3.1. Integration of AI and ML associated with enhanced data interpretation
    • 5.3.2. Increasing availability and affordability of rapid diagnostic kits

6. Infectious Disease Diagnostics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Infectious Disease Diagnostics Market Assessment

  • 7.1. By Type
    • 7.1.1. Products
      • 7.1.1.1. Instruments
      • 7.1.1.2. Reagents and Kits
    • 7.1.2. Services
  • 7.2. By Technology
    • 7.2.1. Genetic Material Based
    • 7.2.2. Immunoassays
    • 7.2.3. Microbial Cultures
    • 7.2.4. Others
  • 7.3. By Technique
    • 7.3.1. Polymerase chain reaction (PCR)
    • 7.3.2. Nucleic Acid Amplification Tests (NAAT)
    • 7.3.3. ELISA
    • 7.3.4. Rapid immunochromatography assays
    • 7.3.5. Others
  • 7.4. By Application
    • 7.4.1. Viral Diseases
    • 7.4.2. Bacterial Diseases
    • 7.4.3. Others
  • 7.5. By End-User
    • 7.5.1. Hospitals
    • 7.5.2. Diagnostic Labs
    • 7.5.3. Others
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.1.2. Canada Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.1.3. Mexico Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.2. Europe
      • 7.6.2.1. France Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.2.2. Germany Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.2.3. United Kingdom Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.2.4. Italy Infectious Disease Diagnostics market size in USD million (2021-2030)
      • 7.6.2.5. Spain Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.2.6. Rest of Europe Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.3.2. Japan Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.3.3. India Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.3.4. Australia Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.3.5. South Korea Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.3.6. Rest of Asia-Pacific Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.4.2. Africa Infectious Disease Diagnostics Market Size in USD million (2021-2030)
      • 7.6.4.3. South America Infectious Disease Diagnostics Market Size in USD million (2021-2030)

8. Infectious Disease Diagnostics Market Company and Product Profiles

  • 8.1. BD
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Bio-Rad Laboratories, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. F. Hoffmann-La Roche Ltd.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Abbott
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. bioMerieux SA
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. QIAGEN
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. DiaSorin S.p.A
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Meridian Bioscience, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Quest Diagnostics
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Thermo Fisher Scientific Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Cepheid
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Siemens Healthcare GmbH
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Ortho Clinical Diagnostics
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Biocare Medical, LLC.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Bruker
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Cardinal Health
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Chembio Diagnostics, Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Novacyt
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Trinity Biotech
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. OJ-Bio Limited
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제